{"nctId":"NCT00675792","briefTitle":"Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)","startDateStruct":{"date":"2008-05"},"conditions":["Anesthesia"],"count":100,"armGroups":[{"label":"Sugammadex","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex","Drug: Rocuronium"]},{"label":"Neostigmine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Neostigmine","Drug: Rocuronium"]}],"interventions":[{"name":"Sugammadex","otherNames":["Org 25969","SCH 900616","MK-8616","Bridion®"]},{"name":"Neostigmine","otherNames":["Prostigmin®"]},{"name":"Rocuronium","otherNames":["Rocuronium bromide","Esmeron®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* male or females who are \\>= 18 and \\<= 65 years of age\n* classified by the American Society of Anesthesiologists (ASA) as Class 1 or 2 or 3;\n* Body Mass Index (BMI) of \\<35 kg/m\\^2;\n* is scheduled to undergo an elective open abdominal surgical procedure under general anesthesia requiring neuromuscular relaxation using rocuronium bromide (maintenance of neuromuscular blockade if required) for endotracheal intubation and requiring neuromuscular blockade reversal;\n* is scheduled to undergo a surgical procedure in a position that does not interfere with the use of TOF-Watch® SX;\n* is scheduled to undergo an elective open abdominal procedure expected to last \\<=4 hours (from start of skin incision to end of last stitch of the skin);\n* have given written informed consent.\n\nExclusion Criteria:\n\n* participants for whom a difficult intubation is expected because of anatomical malformations;\n* is known or suspected to have neuromuscular disorders that may impair neuromuscular blockade;\n* is known or suspected to have significant renal dysfunction (e.g., creatinine clearance \\< 30 mL/min) ;\n* is known or suspected to have significant hepatic dysfunction;\n* is known or suspected to have a (family) history of malignant hyperthermia;\n* is known or suspected to have an allergy to opioids, muscle relaxants or other medications used during general anesthesia;\n* participants for whom the use of neostigmine and/or glycopyrrolate may be contraindicated;\n* participants for whom a pre-established need for postoperative intensive care admission is expected;\n* pregnant or breast-feeding females;\n* have participated in a previous sugammadex clinical trial;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation","description":"Neuromuscular function was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds, and assessing twitch response at the adductor pollicis muscle with a TOF-Watch® SX. The magnitudes (heights) of the first and fourth twitches (T1 and T4) were used to calculate the T4/T1 ratio, where a higher T4/T1 ratio indicates a greater recovery from neuromuscular blockade, with a value of 1.0 indicating complete recovery. After anesthesia, when neuromuscular function was expected to be fully recovered, tracheal extubation was performed, at which time the T4/T1 ratio was measured, with any missing recovery times imputed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.15"},{"groupId":"OG001","value":"0.78","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Post-operative Complications","description":"Post-operative complications include any of the following: procedural pain, nausea, vomiting, incision-site pain, constipation, headache, pyrexia, dizziness and pruritus.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Evidence of Possible Interaction of Sugammadex With Endogenous Compounds or Exogenous Compounds Other Than Rocuronium Bromide","description":"Evidence of adverse events due to a possible interaction of sugammadex with exogenous compounds or endogenous compounds other than rocuronium was recorded.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9","description":"Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds, and assessing T1 and T4 twitch response at the adductor pollicis muscle with a TOF-Watch® SX. Nerve stimulation was continued until the T4/T1 ratio, which indicates the extent of recovery from neuromuscular blockade, achieved a ratio of 0.9, with imputed data included.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":"1.18"},{"groupId":"OG001","value":"7.95","spread":"6.92"}]}]}]},{"type":"SECONDARY","title":"Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8","description":"Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds, and assessing T1 and T4 twitch response at the adductor pollicis muscle with a TOF-Watch® SX. Nerve stimulation was continued until the T4/T1 ratio, which indicates the extent of recovery from neuromuscular blockade, achieved a ratio of 0.8, with imputed data included.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"0.82"},{"groupId":"OG001","value":"6.18","spread":"5.73"}]}]}]},{"type":"SECONDARY","title":"Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7","description":"Neuromuscular function was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds, and assessing T1 and T4 twitch response at the adductor pollicis muscle with a TOF-Watch® SX. Nerve stimulation was continued until the T4/T1 ratio, which indicates the extent of recovery from neuromuscular blockade, achieved a ratio of 0.7, with imputed data included.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"0.72"},{"groupId":"OG001","value":"4.98","spread":"4.98"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":51},"commonTop":["Procedural pain","Nausea","Vomiting","Incision site pain","Constipation"]}}}